Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nautilus Biotechnology, Inc.NAUT · Entity 6679 | Director | June 18, 2026 | June 22, 2026 |
| Roivant Sciences Ltd.ROIV · Entity 3185 | Director | October 01, 2026 | October 05, 2026 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Chief Financial Officer | February 12, 2024 | February 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nautilus Biotechnology, Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.28 · Expires 2036-06-18 | Direct | 45,000 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 45,000 · Balance 45,000 F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).
Roivant Sciences Ltd.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 14,954 |
Ending reported balance
After 2026-10-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 17,750 · Balance 32,704 Row 2 · 2026-10-01 · Sale · Disposed 16,850 · Balance 15,854 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. Row 3 · 2026-10-01 · Sale · Disposed 900 · Balance 14,954 F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2032-07-19 | Direct | 151,416 |
Reported balance
After 2026-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Disposed 17,750 · Balance 151,416 F3: Reflects an award of stock options to purchase Common Shares that is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
F3: Reflects an award of stock options to purchase Common Shares that is fully vested.
Zentalis Pharmaceuticals, Inc.
Report date February 12, 2024 · Filed February 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 451,449 |
Reported balance
After 2024-02-12 transaction · row 1
1 source rowRow 1 · 2024-02-12 · Sale · Disposed 2,573 · Balance 451,449 F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person.
F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kinnate Biopharma Inc.
Report date April 03, 2024 · Filed April 05, 2024
Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.39 · Expires 2030-10-23 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-03 · Disposition to issuer · Disposed 60,751 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2032-06-13 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2033-06-12 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.46 · Expires 2031-06-11 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 22:05 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,750 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001807359-26-000018 · wk-form4_1791237952.xml · derivative · entry 4 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,416 Underlying: Common Stock · 17,750 shares Expires 2032-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 22:05 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 900 | $36.57 | $32,913.00 |
DisclosureSEC source: 0001807359-26-000018 · wk-form4_1791237952.xml · nonDerivative · entry 3 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,954 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 22:05 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 16,850 | $36.08 | $607,948.00 |
DisclosureSEC source: 0001807359-26-000018 · wk-form4_1791237952.xml · nonDerivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,854 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 22:05 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 17,750 | $4.46 | $79,165.00 |
DisclosureSEC source: 0001807359-26-000018 · wk-form4_1791237952.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:56 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 10,531 | $0.00 Strike: $39.57 | $0.00 |
DisclosureSEC source: 0001807359-26-000016 · wk-form4_1789772167.xml · derivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,531 Underlying: Common Shares · 10,531 shares Expires 2036-09-15 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:56 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 5,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001807359-26-000016 · wk-form4_1789772167.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,954 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 22:43 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 600 | $40.38 | $24,228.00 |
DisclosureSEC source: 0001807359-26-000014 · wk-form4_1789684991.xml · nonDerivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,900 F2 · balance_after: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.25 to $40.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 22:43 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 4,338 | $39.65 | $172,001.70 |
DisclosureSEC source: 0001807359-26-000014 · wk-form4_1789684991.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,500 F1 · balance_after: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.25 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 22:34 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 2,179 | $40.94 | $89,208.26 |
DisclosureSEC source: 0001807359-26-000012 · wk-form4_1789425238.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,838 F1 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| July 17, 2026 Filed Jul 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 543 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-029192 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,017 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:34 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,750 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001807359-26-000010 · wk-form4_1782945259.xml · derivative · entry 4 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,166 Underlying: Common Stock · 17,750 shares Expires 2032-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:34 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 2,748 | $34.71 | $95,383.08 |
DisclosureSEC source: 0001807359-26-000010 · wk-form4_1782945259.xml · nonDerivative · entry 3 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,474 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.65 to $34.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:34 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 15,002 | $34.32 | $514,868.64 |
DisclosureSEC source: 0001807359-26-000010 · wk-form4_1782945259.xml · nonDerivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,222 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:34 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 17,750 | $4.46 | $79,165.00 |
DisclosureSEC source: 0001807359-26-000010 · wk-form4_1782945259.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:13 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001807359-26-000008 · wk-form4_1782159224.xml · derivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2036-06-18 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 22:34 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 670 | $0.00 | $0.00 |
DisclosureSEC source: 0001807359-26-000006 · wk-form4_1776810842.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,474 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 22:23 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 41,861 | $28.68 | $1,200,573.48 |
DisclosureSEC source: 0001807359-26-000004 · wk-form4_1773872606.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,804 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $28.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 54 | $22.98 | $1,240.92 |
DisclosureSEC source: 0001140361-26-002085 · form4.xml · nonDerivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,665 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 815 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-002085 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,719 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| October 20, 2025 Filed Oct 23, 2025 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-038997 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,904 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 33,726 | $0.00 Strike: $13.77 | $0.00 |
DisclosureSEC source: 0001140361-25-034929 · form4.xml · derivative · entry 3 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,726 Underlying: Common Shares · 33,726 shares Expires 2035-09-09 F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,661 | $13.77 | $22,871.97 |
DisclosureSEC source: 0001140361-25-034929 · form4.xml · nonDerivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,848 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 14,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-034929 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,509 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. Read SEC document |
| July 17, 2025 Filed Jul 22, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026647 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,985 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 20:37 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001808805-25-000064 · wk-form4_1750883852.xml · derivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). Read SEC document |
| April 17, 2025 Filed Apr 22, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-014802 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,376 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| January 23, 2025 Filed Jan 28, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 180 | $11.21 | $2,017.80 |
DisclosureSEC source: 0001140361-25-002102 · form4.xml · nonDerivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,529 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| January 23, 2025 Filed Jan 28, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-002102 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,709 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| October 21, 2024 Filed Oct 24, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-044060 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,037 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| September 12, 2024 Filed Sep 17, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 4,245 | $12.12 | $51,449.40 |
DisclosureSEC source: 0001140361-24-041233 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,424 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 27,894 | $0.00 Strike: $12.19 | $0.00 |
DisclosureSEC source: 0001140361-24-040987 · form4.xml · derivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,894 Underlying: Common Shares · 27,894 shares Expires 2034-09-09 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 16,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-040987 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,669 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. Read SEC document |
| July 23, 2024 Filed Jul 26, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-034279 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,263 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 21:37 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001808805-24-000050 · wk-form4_1718660238.xml · derivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-14 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). Read SEC document |
| April 24, 2024 Filed Apr 27, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 123 | $10.90 | $1,340.70 |
DisclosureSEC source: 0001140361-24-022617 · form4.xml · nonDerivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,561 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| April 24, 2024 Filed Apr 27, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-022617 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,684 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 20,250 | Not disclosed Strike: $24.46 | Not disclosed |
DisclosureSEC source: 0001415889-24-010429 · form4-04052024_040416.xml · derivative · entry 4 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,250 shares Expires 2031-06-11 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $3.48 | Not disclosed |
DisclosureSEC source: 0001415889-24-010429 · form4-04052024_040416.xml · derivative · entry 3 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2033-06-12 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 20,250 | Not disclosed Strike: $8.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-010429 · form4-04052024_040416.xml · derivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,250 shares Expires 2032-06-13 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 60,751 | Not disclosed Strike: $8.39 | Not disclosed |
DisclosureSEC source: 0001415889-24-010429 · form4-04052024_040416.xml · derivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,751 shares Expires 2030-10-23 F1 · price: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 01:22 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,573 | $11.44 | $29,435.12 |
DisclosureSEC source: 0001725160-24-000043 · wk-form4_1707787354.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,449 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 00:12 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 8,669 | $11.54 | $100,040.26 |
DisclosureSEC source: 0001725160-24-000028 · wk-form4_1707178346.xml · nonDerivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454,022 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:12 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001725160-24-000028 · wk-form4_1707178346.xml · derivative · entry 3 Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-01-31 F4 · derivative.exercise_date: The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:12 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-24-000028 · wk-form4_1707178346.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,691 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 19, 2024 Filed Jan 24, 2024 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-003552 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,538 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| October 16, 2023 Filed Oct 19, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-048775 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,331 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 23:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 888 | $19.91 | $17,680.26 |
DisclosureSEC source: 0001725160-23-000179 · wk-form4_1696634321.xml · nonDerivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 387,691 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 1,125 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2023. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 23:18 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,594 | $19.43 | $89,245.34 |
DisclosureSEC source: 0001725160-23-000179 · wk-form4_1696634321.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 388,579 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 1,125 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2023. Read SEC document |
| September 12, 2023 Filed Sep 15, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 26,595 | $0.00 Strike: $11.22 | $0.00 |
DisclosureSEC source: 0001140361-23-044045 · form4.xml · derivative · entry 2 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,595 Underlying: Common Shares · 26,595 shares Expires 2033-09-11 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 12, 2023 Filed Sep 15, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 17,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-044045 · form4.xml · nonDerivative · entry 1 Epperly Melissa B, · CIK 0001807359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,105 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.